Literature DB >> 33561370

Iris Manifestations in Inadequately Treated Chronic Recurrent Vogt-Koyanagi-Harada Disease.

Soon-Phaik Chee1,2,3,4, May Zun Aung Win5,6.   

Abstract

PURPOSE: To describe the iris changes in chronic recurrent Vogt-Koyanagi-Harada Disease (VKH).
METHODS: Retrospective case series. Clinical features of 3 VKH patients who developed bilateral depigmentation of the iris are described.
RESULTS: Patients had delayed diagnosis and inadequately treated chronic recurrent VKH. Patient 1 presented with bilateral multiple contiguous small granulomatous iris stromal lesions, severe diffuse iris swelling more severe near the iris root, producing peripheral iris undulations. Diffuse iris atrophy and peripheral depigmentation subsequently developed. Patient 2 presented with peripheral iris depigmentation, atrophy of the ciliary zone iris stroma and sparing of the sphincter pupillae, giving a 'sunflower appearance.' Patient 3 had extensive iris depigmentation, atrophy, and transillumination defects involving the entire iris.
CONCLUSION: Uncontrolled bilateral diffuse granulomatous stromal iris inflammation leads to subsequent depigmentation, transillumination defects and atrophy, beginning in the peripheral iris. Sphincter pupillae is initially spared but complete iris atrophy may develop.

Entities:  

Keywords:  Vogt-Koyanagi-Harada disease; iris atrophy; iris depigmentation; iris transillumination defect

Mesh:

Year:  2021        PMID: 33561370     DOI: 10.1080/09273948.2020.1870701

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.728


  2 in total

1.  Bilateral Iris depigmentation, transillumination defects and hypotony in Vogt-Koyanagi-Harada disease.

Authors:  Mohit Garg; Dipankar Das; Harsha Bhattacharjee; Kanika Godani; Madhusmita Mahapatra; Riddhi Raichura
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

Review 2.  miRNA Landscape in Pathogenesis and Treatment of Vogt-Koyanagi-Harada Disease.

Authors:  Fabian Vega-Tapia; Mario Bustamante; Rodrigo A Valenzuela; Cristhian A Urzua; Loreto Cuitino
Journal:  Front Cell Dev Biol       Date:  2021-05-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.